ES2369569T8 - Método para producir cepas rugosas de bacterias y sus usos - Google Patents

Método para producir cepas rugosas de bacterias y sus usos Download PDF

Info

Publication number
ES2369569T8
ES2369569T8 ES06820577T ES06820577T ES2369569T8 ES 2369569 T8 ES2369569 T8 ES 2369569T8 ES 06820577 T ES06820577 T ES 06820577T ES 06820577 T ES06820577 T ES 06820577T ES 2369569 T8 ES2369569 T8 ES 2369569T8
Authority
ES
Spain
Prior art keywords
bacteria
produce rough
rough strains
strains
produce
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES06820577T
Other languages
English (en)
Other versions
ES2369569T3 (es
Inventor
John Lawson Stanford
Cynthia Ann Stanford
Graham Mcintyre
Oscar Adelmo Bottasso
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bioeos Ltd
Immodulon Therapeutics Ltd
Original Assignee
Bioeos Ltd
Immodulon Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioeos Ltd, Immodulon Therapeutics Ltd filed Critical Bioeos Ltd
Application granted granted Critical
Publication of ES2369569T3 publication Critical patent/ES2369569T3/es
Publication of ES2369569T8 publication Critical patent/ES2369569T8/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/36—Adaptation or attenuation of cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/01—Preparation of mutants without inserting foreign genetic material therein; Screening processes therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/32—Mycobacterium
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
ES06820577T 2005-12-21 2006-12-19 Método para producir cepas rugosas de bacterias y sus usos. Active ES2369569T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0526033 2005-12-21
GBGB0526033.6A GB0526033D0 (en) 2005-12-21 2005-12-21 Method
PCT/GB2006/004780 WO2007071978A1 (en) 2005-12-21 2006-12-19 Method of producing rough strains of bacteria and uses thereof

Publications (2)

Publication Number Publication Date
ES2369569T3 ES2369569T3 (es) 2011-12-02
ES2369569T8 true ES2369569T8 (es) 2012-06-26

Family

ID=35840894

Family Applications (1)

Application Number Title Priority Date Filing Date
ES06820577T Active ES2369569T3 (es) 2005-12-21 2006-12-19 Método para producir cepas rugosas de bacterias y sus usos.

Country Status (15)

Country Link
US (2) US8071354B2 (es)
EP (2) EP1963484B1 (es)
JP (1) JP5202330B2 (es)
CN (1) CN101384699B (es)
AT (1) ATE519838T1 (es)
AU (1) AU2006328209B2 (es)
BR (1) BRPI0620291B8 (es)
CA (1) CA2633127C (es)
DK (1) DK1963484T3 (es)
ES (1) ES2369569T3 (es)
GB (1) GB0526033D0 (es)
NZ (1) NZ568810A (es)
PL (1) PL1963484T3 (es)
SI (1) SI1963484T1 (es)
WO (1) WO2007071978A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0716778D0 (en) * 2007-08-29 2007-10-10 Bioeos Ltd Use
GB201120779D0 (en) 2011-12-02 2012-01-11 Immodulon Therapeutics Ltd Cancer therapy
GB201216800D0 (en) * 2012-09-20 2012-11-07 Immodulon Therapeutics Ltd Novel use
GB201322725D0 (en) 2013-12-20 2014-02-05 Immodulon Therapeutics Ltd Cancer therapy
WO2016207646A1 (en) 2015-06-24 2016-12-29 Immodulon Therapeutics Limited A checkpoint inhibitor and a whole cell mycobacterium for use in cancer therapy
CN109414463A (zh) * 2016-02-25 2019-03-01 托马斯·朱利叶斯·波洛迪 治疗慢性传染性疾病的组合物和方法
CN109562155A (zh) * 2016-06-24 2019-04-02 艾普特沐恩生物股份有限公司 激活猪属动物的免疫系统的方法
HUE053488T2 (hu) 2017-06-14 2021-06-28 4D Pharma Res Ltd Baktériumtörzseket tartalmazó készítmények
US11077179B2 (en) 2017-08-10 2021-08-03 Epicgenetics, Inc. Method for treating fibromyalgia and chronic fatigue syndrome
CA3117865A1 (en) * 2018-11-02 2020-05-07 4D Pharma Research Limited Compositions comprising bacterial strains
BR112021010917A2 (pt) 2018-12-12 2021-08-31 4D Pharma Research Limited Composições compreendendo cepas bacterianas parabacteroides para tratamento de câncer
EP4043555A4 (en) * 2020-01-21 2023-01-18 Liaoning Greatest Bio-Pharmaceutical Co., Ltd. USE OF RHODOCOCCUS RUBER CELL WALL SKELETON IN REGENERATIVE MEDICINE

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1054055A (en) 1975-05-27 1979-05-08 Raymond Turcotte Isolation and characterization of phenotypes of mycobacteria
WO1991002562A1 (en) 1989-08-17 1991-03-07 Surgical Laser Products, Inc. Integral end structure for medical laser waveguide
GB8919321D0 (en) * 1989-08-25 1989-10-11 Univ London Treatment of chronic inflammatory conditions
CA2095516A1 (en) 1990-11-05 1992-05-06 Paul F. Turner Urethral inserted applicator for prostate hyperthermia
DK0556248T3 (da) 1990-11-08 1997-10-27 Univ London Mycobacterium som adjuvans til antigener
US5521300A (en) 1991-08-13 1996-05-28 Norval B. Galloway Oligonucleotides complementary to mycobacterial nucleic acids
DE69330263T2 (de) 1992-10-13 2002-04-25 F. Hoffmann-La Roche Ag, Basel Von der SOD Familie abgeleitete Oligonukleotide
US6136529A (en) 1993-09-03 2000-10-24 Gen-Probe Incorporated Nucleic acid probes to Mycobacterium avium complex
US5994346A (en) 1995-02-03 1999-11-30 Regents Of The University Of California Use of exochelins in the preservation of organs for transplant
US5786326A (en) 1995-02-03 1998-07-28 Horwitz; Lawrence D. Method for the treatment of atherosclerosis and vascular injury by prevention of vascular smooth muscle cell proliferation
US5721209A (en) 1995-02-03 1998-02-24 The Regents Of The University Of California Iron chelator and inhibitor of iron-mediated oxidant injury
US6218107B1 (en) 1996-05-22 2001-04-17 Gen-Probe Incorporated Compositions and methods for detecting the presence of Mycobacterium kansassii
US6126939A (en) 1996-09-03 2000-10-03 Yeda Research And Development Co. Ltd. Anti-inflammatory dipeptide and pharmaceutical composition thereof
GB9701897D0 (en) 1997-01-30 1997-03-19 Aqua Health Europ Ltd Vaccine
US7067500B2 (en) 1997-05-02 2006-06-27 Integrated Research Technology, Llc Betaines as adjuvants to susceptibility testing and antimicrobial therapy
US7329410B1 (en) * 1998-09-30 2008-02-12 Corixa Corporation Compositions and method for WT1 specific immunotherapy
DE19911208A1 (de) 1999-03-13 2000-09-14 Walther Carl Kurt Gmbh Steckkupplung zur Verbindung von Rohrleitungen, Schläuchen oder dergleichen
GB0025694D0 (en) 2000-10-19 2000-12-06 Univ London Vaccine
WO2004034961A2 (en) 2001-09-06 2004-04-29 Activbiotics, Inc. Antimicrobial agents and uses thereof
WO2003045319A2 (en) 2001-11-21 2003-06-05 Activbiotics, Inc. Targeted therapeutics and uses thereof
US7078399B2 (en) 2001-12-13 2006-07-18 Activbiotics, Inc. Sulfhydryl rifamycins and uses thereof
US20040014750A1 (en) 2001-12-13 2004-01-22 Michaelis Arthur F. Metal complexes and formulations of rifamycin analogues and uses thereof
WO2003068918A2 (en) 2002-02-11 2003-08-21 Auburn University High-sensitivity real-time polymerase chain reaction for detection of nucleic acids
TW200403076A (en) 2002-06-03 2004-03-01 Activbiotics Inc Intravenous rifalazil formulation and methods of use thereof
AR041171A1 (es) 2002-09-06 2005-05-04 Univ London Modulador inmune
EP1684803B1 (en) 2003-11-14 2010-07-07 UCL Business PLC Immune modulator comprising whole cell tsukamurella bacteria
US7442374B2 (en) 2004-07-19 2008-10-28 Ucl Biomedica Plc Composition for increasing the survival to slaughter rate of piglets
MX2007007882A (es) * 2004-12-27 2007-09-07 Federal Mogul Powertrain Inc Blindaje termico para montaje de motor.

Also Published As

Publication number Publication date
BRPI0620291A2 (pt) 2011-11-08
CA2633127A1 (en) 2007-06-28
BRPI0620291B1 (pt) 2020-12-15
CN101384699B (zh) 2012-10-10
PL1963484T3 (pl) 2012-08-31
BRPI0620291B8 (pt) 2021-05-25
CN101384699A (zh) 2009-03-11
AU2006328209B2 (en) 2012-10-11
JP5202330B2 (ja) 2013-06-05
EP2298860A3 (en) 2012-04-25
WO2007071978A1 (en) 2007-06-28
DK1963484T3 (da) 2011-09-19
EP1963484B1 (en) 2011-08-10
EP1963484A1 (en) 2008-09-03
JP2009520489A (ja) 2009-05-28
US8071354B2 (en) 2011-12-06
NZ568810A (en) 2011-09-30
US8512694B2 (en) 2013-08-20
US20090304749A1 (en) 2009-12-10
EP2298860A2 (en) 2011-03-23
ATE519838T1 (de) 2011-08-15
GB0526033D0 (en) 2006-02-01
SI1963484T1 (sl) 2012-06-29
CA2633127C (en) 2015-08-04
US20120082699A1 (en) 2012-04-05
AU2006328209A1 (en) 2007-06-28
ES2369569T3 (es) 2011-12-02

Similar Documents

Publication Publication Date Title
ES2369569T8 (es) Método para producir cepas rugosas de bacterias y sus usos
MD3359172T2 (ro) Compoziții care conțin tulpini bacteriene
BR112013011263A2 (pt) "composição nematicida, e método para controlar nematódeos"
PH12015501172A1 (en) Composition comprising biological control agents
ATE530669T1 (de) Markierte mikroorganismen und entsprechende markierungsverfahren
BRPI0807132A2 (pt) enzimas para o tratamento de lignocelulósicos, ácidos nucléicos que codificam as mesmas, e metodos e uso das mesmas
DE602006015665D1 (de) Probiotische enterokokken für eine verbesserte immunität
MX348797B (es) Microorganismos probioticos como agentes activos para mejorar el brillo de la tez de la piel.
MX351083B (es) Métodos para el tratamiento de trastornos oncológicos usando cambiadores epimetabólicos, moléculas intracelulares multidimensionales, o influenciadores ambientales.
WO2010085795A3 (en) Novel pasteuria strain
WO2005060707A3 (en) Methods of use of probiotic lactobacilli for companion animals
AR065275A1 (es) Proceso para tratar sustancias contaminadas con metales pesados
ZA201109086B (en) Prevention and treatment of allergic diarrhoea
MX2012006629A (es) Microorganismos probioticos como agentes activos contra cambios en microrelieve de la piel.
PH12015501273A1 (en) Probiotic strains for the treatment and/or prevention of diarrhea
WO2018004224A3 (ko) 신규 스포리치아과 미생물 및 그의 용도
MX356959B (es) Cepa paenibacillus alvei ts-15 y su uso en el control de organismos patogenicos.
WO2005092924A8 (en) Rab9a, rab11a, and modulators thereof related to infectious disease
MX2021004150A (es) Composiciones que comprenden cepas bacterianas.
RS54777B1 (sr) Postupak za biološku borbu protiv pseudomonas
ES2557813B2 (es) Composición iniciadora de la fermentación que comprende cepas de microorganismos libres e inmovilizados
AR071018A1 (es) Recipientes y metodos para la reduccion o eliminacion de bacterias en huevos para consumo
WO2011081916A3 (en) Educational methods, kits and systems to create memorabilia
ITRM20080052A1 (it) Metodo igienizzante in grado di ripristinare l'equilibrio naturale della flora batterica e/o smantellare completamente microrganismi, funghi ed altri agenti patogeni o maleodoranti dalla superficie della pelle.
CL2017003446A1 (es) Extracto de origen bacteriano producido por la bacteria marina kocuria sp y su uso para generar estructuras poliméricas con superficies bioactivas capaces de inhibir la formación de biopelículas microbianas